Skip to main content
Erschienen in:

02.05.2023 | Assisted Reproduction Technologies

Ovulation induction with letrozole and dexamethasone in infertile patients with letrozole-resistant polycystic ovary syndrome

verfasst von: Michael F. Neblett II, Sarah C. Baumgarten, Samir N. Babayev, Chandra C. Shenoy

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess efficacy of adjuvant dexamethasone during letrozole cycles for ovulation induction (OI) in women with letrozole-resistant polycystic ovary syndrome (PCOS).

Methods

We retrospectively evaluated 42 cycles of OI from 28 infertile women with letrozole-resistant PCOS between September 2019 and November 2022. Letrozole was initiated on cycle day 3 for 5 days and increased via a stair-step approach to 7.5 mg as indicated. Patients were deemed letrozole-resistant if no dominant follicle was identified on transvaginal ultrasound following this dose. Resistant patients then received 5 additional days of letrozole 7.5 mg with low-dose dexamethasone 0.5 mg for 7 days and had a repeat ultrasound. The primary outcome was ovulation rate determined by the presence of a dominant follicle on ultrasound. Secondary outcomes included endometrial thickness, number of measurable follicles, and pregnancy outcomes among responders.

Results

Twenty-two of 28 (79%) letrozole-resistant PCOS patients had evidence of ovulation after the addition of dexamethasone in 35 out of 42 (83%) cycles. Clinical pregnancy occurred in 20% of ovulatory cycles with a cumulative rate of 32%. All clinical pregnancies resulted in a live birth. Patients who responded to adjuvant dexamethasone were more likely to have a shorter duration of infertility; however, there were no differences in other demographics, serum androgens including DHEA-S, or pretreatment glycemic status.

Conclusion

Adding dexamethasone to letrozole increased ovulation rates in letrozole-resistant PCOS patients undergoing OI with similar pregnancy outcomes to prior studies. The addition of dexamethasone is an effective, inexpensive, and safe option for PCOS patients otherwise at risk for cycle cancelation.
Literatur
1.
Zurück zum Zitat Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.CrossRefPubMed Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.CrossRefPubMed
2.
Zurück zum Zitat Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.CrossRefPubMed Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.CrossRefPubMed
3.
Zurück zum Zitat Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
4.
Zurück zum Zitat Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.e25.CrossRefPubMed Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.e25.CrossRefPubMed
5.
Zurück zum Zitat Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110:364–79.CrossRefPubMedPubMedCentral Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110:364–79.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119–29.CrossRefPubMedPubMedCentral Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119–29.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Insogna IG, Lanes A, Hariton E, Blake-Lamb T, Schilling S, Hornstein MD. Self-reported barriers to accessing infertility care: patient perspectives from urban gynecology clinics. J Assist Reprod Genet. 2020;37:3007–14.CrossRefPubMedPubMedCentral Insogna IG, Lanes A, Hariton E, Blake-Lamb T, Schilling S, Hornstein MD. Self-reported barriers to accessing infertility care: patient perspectives from urban gynecology clinics. J Assist Reprod Genet. 2020;37:3007–14.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat MoazamiGoudarzi Z, Fallahzadeh H, Aflatoonian A, Mirzaei M. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: a systematic review and meta-analysis. Iran J Reprod Med. 2014;12:531–8. MoazamiGoudarzi Z, Fallahzadeh H, Aflatoonian A, Mirzaei M. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: a systematic review and meta-analysis. Iran J Reprod Med. 2014;12:531–8.
9.
Zurück zum Zitat Bordewijk EM, Ng KYB, Rakic L, Mol BWJ, Brown J, Crawford TJ, et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;2:Cd001122.PubMed Bordewijk EM, Ng KYB, Rakic L, Mol BWJ, Brown J, Crawford TJ, et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;2:Cd001122.PubMed
10.
Zurück zum Zitat Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.CrossRefPubMedPubMedCentral Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Isaacs JD, Lincoln SR, Cowan BD. Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertil Steril. 1997;67:641–3.CrossRefPubMed Isaacs JD, Lincoln SR, Cowan BD. Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertil Steril. 1997;67:641–3.CrossRefPubMed
12.
Zurück zum Zitat Brann D, O’Conner J, Wade M, Mahesh V. LH and FSH subunit mRNA concentrations during the progesterone-induced gonadotropin surge in ovariectomized estrogen-primed immature rats. Mol Cell Neurosci. 1992;3:171–8.CrossRefPubMed Brann D, O’Conner J, Wade M, Mahesh V. LH and FSH subunit mRNA concentrations during the progesterone-induced gonadotropin surge in ovariectomized estrogen-primed immature rats. Mol Cell Neurosci. 1992;3:171–8.CrossRefPubMed
13.
Zurück zum Zitat Trott EA, Plouffe L Jr, Hansen K, Hines R, Brann DW, Mahesh VB. Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Fertil Steril. 1996;66:484–6.CrossRefPubMed Trott EA, Plouffe L Jr, Hansen K, Hines R, Brann DW, Mahesh VB. Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Fertil Steril. 1996;66:484–6.CrossRefPubMed
14.
Zurück zum Zitat Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril. 2002;78:1001–4.CrossRefPubMed Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril. 2002;78:1001–4.CrossRefPubMed
15.
Zurück zum Zitat Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006;21:1805–8.CrossRefPubMed Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006;21:1805–8.CrossRefPubMed
16.
Zurück zum Zitat Lobo RA, Paul W, March CM, Granger L, Kletzky OA. Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol. 1982;60:497–501.PubMed Lobo RA, Paul W, March CM, Granger L, Kletzky OA. Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol. 1982;60:497–501.PubMed
17.
Zurück zum Zitat Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril. 1984;41:844–8.CrossRefPubMed Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril. 1984;41:844–8.CrossRefPubMed
18.
Zurück zum Zitat Andersen M, Glintborg D. Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT? Eur J Endocrinol. 2018;179:D1-d14.CrossRefPubMed Andersen M, Glintborg D. Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT? Eur J Endocrinol. 2018;179:D1-d14.CrossRefPubMed
19.
Zurück zum Zitat Thomas S, Woo I, Ho J, Jones T, Paulson R, Chung K, et al. Ovulation rates in a stair-step protocol with letrozole vs clomiphene citrate in patients with polycystic ovarian syndrome. Contracept Reprod Med. 2019;4:20.CrossRefPubMedPubMedCentral Thomas S, Woo I, Ho J, Jones T, Paulson R, Chung K, et al. Ovulation rates in a stair-step protocol with letrozole vs clomiphene citrate in patients with polycystic ovarian syndrome. Contracept Reprod Med. 2019;4:20.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Mikolajczyk RT, Stanford JB, Ecochard R. Multilevel model to assess sources of variation in follicular growth close to the time of ovulation in women with normal fertility: a multicenter observational study. Reprod Biol Endocrinol. 2008;6:61.CrossRefPubMedPubMedCentral Mikolajczyk RT, Stanford JB, Ecochard R. Multilevel model to assess sources of variation in follicular growth close to the time of ovulation in women with normal fertility: a multicenter observational study. Reprod Biol Endocrinol. 2008;6:61.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017;108:393–406.CrossRefPubMed Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017;108:393–406.CrossRefPubMed
22.
Zurück zum Zitat Farzaneh F, Afshar F. Comparison of ovulation induction with letrozole plus dexamethasone and letrozole alone in infertile women with polycystic ovarian disease: An RCT. Int J Reprod Biomed. 2020;18:307–10.PubMedPubMedCentral Farzaneh F, Afshar F. Comparison of ovulation induction with letrozole plus dexamethasone and letrozole alone in infertile women with polycystic ovarian disease: An RCT. Int J Reprod Biomed. 2020;18:307–10.PubMedPubMedCentral
23.
Zurück zum Zitat Zhu X, Fu Y. Extending letrozole treatment duration is effective in inducing ovulation in women with polycystic ovary syndrome and letrozole resistance. Fertil Steril. 2023;119:107–13.CrossRefPubMed Zhu X, Fu Y. Extending letrozole treatment duration is effective in inducing ovulation in women with polycystic ovary syndrome and letrozole resistance. Fertil Steril. 2023;119:107–13.CrossRefPubMed
24.
Zurück zum Zitat Mejia RB, Summers KM, Kresowik JD, Van Voorhis BJ. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111:571-8.e1.CrossRefPubMed Mejia RB, Summers KM, Kresowik JD, Van Voorhis BJ. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111:571-8.e1.CrossRefPubMed
25.
Zurück zum Zitat Ehrmann DA, Breda E, Corcoran MC, Cavaghan MK, Imperial J, Toffolo G, et al. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004;287:E241–6.CrossRefPubMed Ehrmann DA, Breda E, Corcoran MC, Cavaghan MK, Imperial J, Toffolo G, et al. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004;287:E241–6.CrossRefPubMed
Metadaten
Titel
Ovulation induction with letrozole and dexamethasone in infertile patients with letrozole-resistant polycystic ovary syndrome
verfasst von
Michael F. Neblett II
Sarah C. Baumgarten
Samir N. Babayev
Chandra C. Shenoy
Publikationsdatum
02.05.2023
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 6/2023
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-023-02817-9

Neu im Fachgebiet Gynäkologie und Geburtshilfe

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.